Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of July 2022, with the report dated July 08, 2022. The document serves as a transaction notification regarding a specific share acquisition by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a single insider transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares (Dividend Re-investment) |
| Instrument | Ordinary Shares of 25 pence each (ISIN: GB0009252882) |
| Share Price | £18.0992 |
| Volume | 18 shares |
| Transaction Date | July 04, 2022 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details an initial notification of a personal transaction by Mr. D Redfern, Chief Strategy Officer, involving the re-investment of dividends paid on July 1, 2022, into shares held within an Individual Savings Account (ISA).
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is strictly a compliance report for a PDMR transaction.
Key Facts for Investor Verification
- The transaction was an acquisition of 18 shares by the Chief Strategy Officer via dividend re-investment.
- The transaction occurred on the London Stock Exchange at a price of £18.0992 per share.
- This filing does not contain financial performance data for GSK plc.